Prediction of adverse pregnancy outcome by first-trimester maternal serum PAPP-A. Preeclampsia occurs in 2 to 5% of all pregnancies in developed countries. Together with IUGR it consists one of the leading reasons for perinatal death and childhood handicap. This is why many authors are looking for a widely usable and easy to perform test for evaluation of the patients at risk for preeclampsia an IUGR. PAPP-A is a protein complex produced by the developing trophoblast which is used as a marker for Downs' syndrome. Previous studies have shown an association between low first trimester maternal serum PAPP-A and subsequent development of pregnancy complications.